I remember when we had a broad and diverse portfolio of medications, behind which we built a strong name for ourselves
what’s going on now? We have an expiring oncology product with nothing much else worth a mention.
most markets in Europe are down to only two business units (Onco + The other crap)
we let all our relent leave and are so thin on the ground we can expect to mess up anything else we bring to market
it’s a disgrace what the leaders have let this company become
only way out is a big merger
what’s going on now? We have an expiring oncology product with nothing much else worth a mention.
most markets in Europe are down to only two business units (Onco + The other crap)
we let all our relent leave and are so thin on the ground we can expect to mess up anything else we bring to market
it’s a disgrace what the leaders have let this company become
only way out is a big merger